Y. Hinai, S. Motoyama, T. Niioka and M. Miura
Cancer patients treated with cisplatin chemotherapy frequently experience drug-induced nephrotoxicity. Clinical studies using a single chemotherapeutic regimen or large sample sizes for patients with the SLC22A2 808T allele have not been reported. The change rate of the estimated glomerular filtration rate (eGFR) was used for the evaluation of cisplatin-induced nephrotoxicity. The change rate of eGFR for each patient receiving FP chemotherapy was calculated according to the following formula: change rate = (pre-chemotherapy – post-chemotherapy)/pre-chemotherapy. The eGFR after FP chemotherapy was significantly lower than that before chemotherapy, and the mean difference in eGFR was 25·7 mL/min (P < 0·01). Our present study was estimated with a single chemotherapeutic regimen, eGFR, is calculated using serum creatinine, age, and the sex of the patient, and sample sizes of 25 patients with SLC22A2 808T allele.